About 87% of Israel's medical cannabis patients smoke their medicine, and roughly 98% of licensed purchases are for flower (StratCann; ICBC, citing the Jerusalem Post) — a share Israel's medical establishment has spent three years trying to bring down, most recently with a proposal to phase smoking out entirely. Whatever happens to that proposal, the practical question for patients is the same: what are the alternatives, how do they actually differ, and are they any good? This guide covers the non-smoked formats available in Israel today.
This guide is informational and is not medical advice. Changing the route by which you take a prescribed medicine changes its dose and its effects — do it with your prescribing physician, not on your own.
Why this is on the agenda
In May 2026 a Health Ministry committee recommended ending the use and marketing of smoked medical cannabis within three years, moving patients to extracts or precision inhalers on grounds of health risk and inconsistent absorption. The health minister froze the recommendations three days later, so nothing has changed yet — the full story is in our guide to Israel's 2026 smoked-cannabis proposal.
The professional pressure predates that committee. The Israel Medical Association recommended in 2023 that medical cannabis be administered primarily in oil form, noting that smoking "is more typical of recreational consumption than of consumption as part of medical treatment" and that the local habit of mixing cannabis with tobacco raises tobacco addiction and smoking rates (Times of Israel).
What is actually available in Israel
Israeli medical cannabis is dispensed under standardised product categories. In practice a licensed patient chooses between:
- Dried inflorescence (flower), typically sold in 10-gram packages, intended for smoking or vaporising.
- Oils / extracts, typically sold in 10 ml bottles for oral or sublingual use (StratCann).
- The SyqeAir metered-dose inhaler — an Israeli-developed device, and the only metered inhaler for dried medical cannabis on the market (StratCann).
- Oil-based vaporiser cartridges, delivered through the VapePod, which the Israeli Ministry of Health approved as a medical device in 2018 (Kanabo Research).
Generic vape pens are not currently approved through the medical programme (StratCann) — the devices above are the sanctioned route. All products, whatever the format, are made under Israel's IMC-GMP rulebook — see IMC-GAP and IMC-GMP standards explained.
The real difference: how fast, how much, how long
The choice between formats is a pharmacology decision more than a preference. Inhalation and oral dosing behave very differently:
- Onset. Inhaled cannabis takes effect within about 10 minutes. Swallowed oil is delayed one to three hours.
- Bioavailability. Inhalation delivers roughly 10–35% of the THC, with combustion reaching at most about 25%. Oral dosing delivers only about 4–12%, because the liver metabolises most of it before it reaches circulation.
- Duration. Inhaled effects run about 2–4 hours; oral effects run 6–12 hours.
(Ranges from a clinical review in The Permanente Journal, 2024.)
Those three lines explain most of what patients experience. Inhaling gives fast, self-titratable relief — you feel it, so you know when to stop — which is why it dominates for breakthrough pain, nausea and acute distress. Oil gives slower, longer, steadier coverage, which suits background symptom control and overnight dosing, but it is easy to overshoot: because the effect arrives late, patients who "top up" at 45 minutes often end up far too high two hours later. Oil also loses far more of the dose to first-pass liver metabolism, which is why the milligram figures on an oil bottle are not comparable to the milligrams in a gram of flower.
The regulators' complaint about smoking is the flip side of its advantage: nobody — patient, physician or ministry — can say how much THC was actually delivered by a joint. Combustion also destroys some of the active compounds and produces the same tar and irritants as tobacco smoke.
The Israeli case for metered inhalers
Israel is where the strongest evidence for precise inhaled dosing was generated. In a randomised, double-blind, placebo-controlled trial run at Rambam Health Care Campus in Haifa, patients with chronic neuropathic pain and complex regional pain syndrome received tightly controlled THC doses of 0.5 mg and 1.0 mg through a selective-dose inhaler, and reported significant pain relief with a favourable side-effect profile (Almog et al., European Journal of Pain, 2020).
The scale of that gap is worth sitting with. One gram of 15%-THC flower contains about 150 milligrams of THC — and, at the bioavailability figures above, still delivers tens of milligrams systemically, against a trial dose measured in fractions of one. A companion open-label study of the same device in hospitalised patients recorded inhaled intake of about 51 mg a day, against roughly 1,000 mg a day before admission (Palliative & Supportive Care, 2020).
The honest caveats matter here. These were small trials, in narrow pain populations, with a single device — and the Almog trial was run in partnership with Syqe Medical, which makes that device and stands to benefit from exactly the policy shift under discussion. They establish that low, precise inhaled doses can work; they do not establish that every patient on 30 grams a month can be moved to milligrams without losing benefit. That is the question the Health Ministry committee wants answered by more research, and the reason patient groups objected to setting a deadline before the answers exist.
Practical trade-offs
Cost. Medical cannabis is not in Israel's national health basket, so patients largely pay out of pocket, and devices add a hardware cost on top of the product. See how much medical cannabis costs in Israel.
Availability. Not every authorised pharmacy stocks every format or device, and supply of specific oil profiles fluctuates. Confirm stock before committing to a switch.
Titration. If you move from flower to oil, start low and go slow, and give each dose a full two hours before judging it.
Your licence. Your authorisation specifies a monthly quantity and, in practice, a product type. Changing format is a prescription change, not a shopping decision — see how to get a medical cannabis licence in Israel.
Composition. Oils and flower differ in their cannabinoid and terpene profiles, and the ratio matters as much as the milligrams — background in the entourage effect explained.
The bottom line
Non-smoked medical cannabis in Israel is not theoretical: oils, an approved oil vaporiser and a metered-dose inhaler are all available now, and the strongest evidence for precision dosing came out of an Israeli hospital. Whether the country forces the switch is unsettled. Patients who would rather choose than be moved have the option today — the conversation to have with your physician is about dose equivalence and timing, not about which format is "better."
For the wider access picture, return to our Patients hub; for the regulatory fight behind all of this, see Israel's 2026 smoked-cannabis proposal.
Compiled and reviewed by Tamar Levin, Editor. Sources are linked inline. This guide is informational and is not medical or legal advice; consult a licensed physician about your own treatment.
More on this topic: Patient Access.